Maha Katabi, PhD, CFA is a General Partner of Sofinnova Investments. She is an experienced investor with over two decades of managing public and private biotech companies through bull and bear markets. Maha is currently a board member of Aerovate (AVTE), Quanta, RayzeBio (RYZB), Star, and Vera (VERA). She previously was a board member of Amplyx (acquired by Pfizer), Gyroscope (acquired by Novartis) and Northsea.Prior to joining Sofinnova in 2019, Maha was Managing Partner of Oxalis Capital and prior to that was Partner at Sectoral Asset Management. There, she formed and led a dedicated team to manage investments in private companies and was a Portfolio Manager for a family of funds investing in small cap healthcare companies. Maha co-invested with Sofinnova in multiple companies: Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), and Trius Therapeutics (TSRX-acquired by Cubist). Earlier in her career, she worked as an associate and principal investing in seed and early stage biotech at T2C2/Bio and Ventures West.Maha received a Ph.D. in Pharmacology and a B.Sc. in Biology at McGill University and was awarded a Cancer Research Society scholarship. She is a CFA charterholder.
